Nature Communications (Aug 2020)
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
- Barbara Oldrini,
- Nuria Vaquero-Siguero,
- Quanhua Mu,
- Paula Kroon,
- Ying Zhang,
- Marcos Galán-Ganga,
- Zhaoshi Bao,
- Zheng Wang,
- Hanjie Liu,
- Jason K. Sa,
- Junfei Zhao,
- Hoon Kim,
- Sandra Rodriguez-Perales,
- Do-Hyun Nam,
- Roel G. W. Verhaak,
- Raul Rabadan,
- Tao Jiang,
- Jiguang Wang,
- Massimo Squatrito
Affiliations
- Barbara Oldrini
- Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center, CNIO
- Nuria Vaquero-Siguero
- Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center, CNIO
- Quanhua Mu
- Division of Life Science, Department of Chemical and Biological Engineering, Center of Systems Biology and Human Health and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology
- Paula Kroon
- Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center, CNIO
- Ying Zhang
- Beijing Neurosurgical Institute, Capital Medical University
- Marcos Galán-Ganga
- Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center, CNIO
- Zhaoshi Bao
- Division of Life Science, Department of Chemical and Biological Engineering, Center of Systems Biology and Human Health and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology
- Zheng Wang
- Beijing Neurosurgical Institute, Capital Medical University
- Hanjie Liu
- Beijing Neurosurgical Institute, Capital Medical University
- Jason K. Sa
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
- Junfei Zhao
- Department of Systems Biology, Columbia University
- Hoon Kim
- The Jackson Laboratory for Genomic Medicine
- Sandra Rodriguez-Perales
- Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Center, CNIO
- Do-Hyun Nam
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
- Roel G. W. Verhaak
- The Jackson Laboratory for Genomic Medicine
- Raul Rabadan
- Department of Systems Biology, Columbia University
- Tao Jiang
- Beijing Neurosurgical Institute, Capital Medical University
- Jiguang Wang
- Division of Life Science, Department of Chemical and Biological Engineering, Center of Systems Biology and Human Health and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology
- Massimo Squatrito
- Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center, CNIO
- DOI
- https://doi.org/10.1038/s41467-020-17717-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 10
Abstract
Chemotherapy resistance in recurrent gliomas is a large hurdle for successful therapy. Here, the authors show that some recurrent gliomas harbour O-6-methylguanine-DNA methyltransferase (MGMT) genomic rearrangements, and in vitro and in vivo these contribute to temozolomide resistance.
